Personalized Oncology Kiyatec provides patient-specific tumor models to predict treatment response, creating an opportunity to partner with hospital systems and oncology networks seeking precision medicine solutions that reduce ineffective therapies and improve outcomes.

Clinical Validation Their approach is validated through engagements with leading cancer hospitals, top pharmaceutical companies, and the NCI, supporting a sales narrative around credibility and adoption potential for pharma and research institutions.

Strategic Leadership Recent leadership moves including a CEO appointment and a strategic advisor with deep industry pedigree from Myriad Genetics can be leveraged to open executive-led conversations and sponsorship for larger pilots and collaborations.

Series C Backing Strong funding history, including an $18M Series C led by Bruker, signals financial vitality and capability to scale collaborations, contracts, and multi-site studies with biotech and pharma partners.

Clinical Trial Footprint Ongoing and robust clinical trials position Kiyatec to offer trial-ready services and data to pharma developers, enabling partnerships for drug development, screening, and companion diagnostics.